News & Updates
Stay informed with the latest from the MCLA community.
Larry's Story: Living with MCL Since 2012
Larry Fagan, an MCLA Board Member, was diagnosed with mantle cell lymphoma in 2012 — just after retiring and his son's college graduation. He shares his treatment journey at Stanford, the unusual way he learned about his diagnosis, and how an online community of MCL patients eventually led him to help start the MCLA.
Sonrotoclax
Next-Generation Therapy Sonrotoclax Receives FDA Approval
Newly approved therapy expands treatment choices and signals continued progress for people living with MCL. Sonrotoclax (brand name Beqalzi) is the first BCL-2 inhibitor formally approved for mantle cell lymphoma, cleared for patients whose disease has returned or stopped responding after at least two prior treatments.
Mosunetuzumab + Polatuzumab vedotin
Targeted Immunotherapy Combo Shows Strong Results in Relapsed Mantle Cell Lymphoma
A new Phase 2 study published in Blood in April 2026 reports an 88% response rate for a fixed-duration combination of mosunetuzumab and polatuzumab vedotin in patients with mantle cell lymphoma whose disease has returned after a BTK inhibitor.
Tecartus
FDA Grants Full Approval to Tecartus for Relapsed Mantle Cell Lymphoma
New long-term data from the ZUMA-2 trial supported the FDA's full approval of Tecartus in April 2026, with a 91% response rate in adults with relapsed or refractory mantle cell lymphoma after prior therapies including BTK inhibitors.
Acalabrutinib + Venetoclax + Rituximab
FDA Launches Real-Time Clinical Trial Pilot — and Mantle Cell Lymphoma Is at the Center
The FDA has selected a mantle cell lymphoma study as one of the first trials in a new pilot program that lets regulators see clinical trial data in real time — a move that could speed access to promising treatments for patients.
Our Story - How MCLA started
When mantle cell lymphoma changes your world overnight, you go searching for answers. Too often, you don't find them. This is the story of why we built MCLA—and what comes next.